Brain Tumor Breakthrough: Blocking Fructose Metabolism Shows Promise in Glioblastoma Treatment

Northwestern Medicine scientists have discovered a surprising vulnerability in glioblastoma, the most aggressive form of brain cancer: a dependence on fructose metabolism to suppress the immune system and fuel tumor growth. This finding, published today, March 17, 2026, in the Proceedings of the National Academy of Sciences, suggests a new therapeutic target to improve treatment outcomes for this devastating disease.

Glioblastoma: A Formidable Foe

Glioblastoma is notoriously tough to treat, with a five-year survival rate of less than 7%, according to the National Brain Tumor Society. Its resistance to conventional therapies is largely attributed to the complex tumor microenvironment, which includes cells that actively suppress the immune response.

How Tumors Hijack Sugar Metabolism

The study reveals that specialized immune cells within glioblastoma tumors, specifically microglia, metabolize fructose. This process doesn’t nourish the tumor directly, but instead actively suppresses the immune system, allowing the cancer to thrive. Researchers found that microglia uniquely express a fructose transporter, GLUT5, enabling them to transport and metabolize fructose within the tumor microenvironment. This is the first study to identify this sugar pathway as a driver of immune suppression in brain tumors.

Blocking Fructose Metabolism: A Potential Game Changer

In mouse models, blocking the GLUT5 fructose transporter led to dramatic results. “Across several mouse models, when we removed the fructose transporter, the tumors simply didn’t grow,” said Jason Miska, assistant professor of neurological surgery at Northwestern University Feinberg School of Medicine. “It was far more dramatic than we anticipated.”

Removing the transporter reactivated tumor-killing immune cells, including CD8+ T-cells, and increased the production of cytokines, signaling molecules that promote inflammation and an immune response. The research indicates that fructose metabolism in microglia is essential for promoting tumorigenesis.

The Immune System’s Role in Tumor Rejection

The study highlights a complex interplay between different parts of the immune system. Blocking fructose metabolism not only made microglia more inflammatory but also activated other immune cells, leading to a more robust anti-tumor response. Leah Billingham, a Northwestern postdoctoral fellow and co-first author of the study, explained that this isn’t just about microglia acting alone, but rather an intricate interaction that impacts tumor rejection.

Fructose in the Brain: A Unique Paradox

Interestingly, the role of fructose appears to differ in the brain compared to other organs. While fructose consumption is often linked to inflammation in conditions like colon cancer and diabetic neuropathy, it seems to suppress inflammation within the brain, while still aiding tumor growth. “What’s interesting here is that in the brain, it seems to be working differently,” Miska noted. “It still helps the brain tumor grow, but now we’re seeing something very different in the brain than we see in the rest of the body.”

Future Directions: Developing Fructose Transport Inhibitors

The Northwestern team is now focused on identifying drugs that can specifically block cells from absorbing fructose. These potential inhibitors will then be tested in preclinical trials, combined with standard-of-care therapies and immunotherapies, to assess their ability to enhance treatment effectiveness. “The challenge with glioblastoma is that the standard of care has barely changed in 20 years,” Miska said. “That’s why identifying an entirely new therapeutic approach like this is so exciting.”

Key Takeaways

• Glioblastoma tumors utilize fructose metabolism to suppress the immune system.
• Blocking the fructose transporter, GLUT5, in microglia significantly inhibited tumor growth in mouse models.
• This discovery offers a promising new therapeutic target for glioblastoma treatment.
• Further research is underway to develop drugs that can block fructose absorption in tumor cells.

Sources:

Northwestern Medicine News, Memesita, bioRxiv, PMC